Fate Therapeutics Inc (FATE) was Resumed by H.C. Wainwright to “Buy” and the brokerage firm has set the Price Target at $9. H.C. Wainwright advised their investors in a research report released on Jul 28, 2016.
Fate Therapeutics Inc opened for trading at $2 and hit $2.49 on the upside on Thursday, eventually ending the session at $1.98, with a gain of 5.88% or 0.11 points. The heightened volatility saw the trading volume jump to 31,94,122 shares. Company has a market cap of $57 M.
Fate Therapeutics Inc. (Fate Therapeutics) is a clinical-stage biopharmaceutical company engaged in the development of programmed cellular therapeutics. The Company has a number of programmed cellular therapeutic candidates in development and research. The Company’s development programs include ProHema (FT1050-modulated hematopoietic cells within umbilical cord blood (UCB)) which targets Hematologic Malignancies and Inherited Metabolic Disorders therapeutic conditions and are in Phase II Phase Ib and Phase Ib respectively. Its development programs also include Programmed hematopoietic cells within mobilized peripheral blood (mPB) (FT1050+FT4145-modulated mPB) which is for Hematologic and Malignancies therapeutic area and is in IND enablement-stage. Its research programs include Programmed Hematopoietic Cells human induced pluripotent stem cells (hiPSC)-derived Hematopoietic Cells and hiPSC-derived Myogenic Progenitor Cells.